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Background
In lung cancer, reliable prognostic indicators of the risk
of recurrence are still not available. Alternative splicing
represents a potential biomarker of diagnosis, prognosis,
invasiveness, and response to therapy in different
tumors [1], including lung cancer [2].
Human MENA (hMENA) is an actin regulatory protein
that modulates cell adhesion and migration [3]. We have
isolated three hMENA splice variants, namely hMENA,
hMENA11a and hMENAΔv6, impacting differently cell
shape and function. hMENA11a expression ensures the
integrity of cell-cell adhesion and is associated with an
epithelial phenotype, whereas hMENAΔv6 is related to a
mesenchymal invasive phenotype. The splicing of
hMENA, relevant to epithelial mesenchymal transition, is
also regulated by microenvironmental cues [4].
The dynamic reciprocity between tumor and stroma
influences the tumor tissue architecture including the T
cell localization. This, proposed as a prognostic marker [5],
is a prerequisite for antitumor immune surveillance and
recently the antibody blockade of immune checkpoints is a
new reality in lung cancer treatment [6,7].
Materials and methods
Pan-hMENA and specific hMENA11a Abs were tested by
immunohistochemistry on duplicate TMA from 248 N0
NSCLC, and clinical factors (sex, age, histology, grading,
T-size, number of resected nodes, RN) were correlated to
3-yr disease-free (DFS), cancer-specific (CSS), and overall
survival (OS) using a Cox model. ROC analysis provided
optimal cut-off values and model validation. A logistic
equation including regression analysis coefficients was
constructed to estimate individual patients’ probability
(IPP) of relapse. Internal cross-validation (100 simulations
with 80% of the dataset) and external validation was
accomplished.
A panel of antibodies recognizing CD3, CD4, CD8, CD20
molecules has been employed for the characterization and
localization of lymphocytes, by immunohistochemistry.
Results
In the series of N0 NSCLC patients (median follow-up:
36 months, range 1-96), Pan-hMENA and hMENA11a
were the only biological variables displaying significant
correlation with outcome(s), confirmed by the cross-
validation (replication rate: 78%, 83%), with a prognostic
model accuracy of 61% (standard error 0.04, p=0.0001).
The subgroup of patients with High Pan-hMENA/Low
hMENA11a relative expression fared significantly better
than the other 3 groups (p≤0.002 for all outcomes). On
the basis of the combination between this molecular
hybrid variable and T-size and RN, a 3-risk class stratifica-
tion model was generated, discriminating between patients
at different risk of relapse, cancer-related death, and death
for any cause, with a prognostic accuracy of 61% (standard
error 0.03, p=0.01), according to ROC analysis and
validated in an independent dataset of 133 patients.
The correlation between hMENA isoforms and the pat-
tern of expression and localization of lymphocytes in the
different groups of risk of relapse identified is under
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Conclusions
The hMENA splicing program is an early prognostic
marker of NSCLC patients and may represent a surrogate
marker of a permissive or not tumor microenvironment
for lymphocyte recruitment.
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